Last checked at 8 Jun 2020 07:00
Creo Medical Group plc
("Creo" or the "Company")
Institution of Engineering and Technology Prize nomination
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that Creo Medical founder and Chief Technology Officer, Chris Hancock, has been shortlisted for the Institution of Engineering and Technology's (IET) A F Harvey Engineering Research Prize.
The IET is one of the world's largest engineering institutions with over 169,000 members in 150 countries and the prize is open to candidates globally. The A F Harvey Engineering Research Prize is awarded annually in recognition of an outstanding achievement in engineering research in the fields of medical, microwave and radar or laser/optoelectronic engineering. This year's theme is medical engineering and technology.
The prize winner will be chosen from a shortlist of five candidates and announced in December 2020. The winning researcher will deliver a keynote lecture on their research at IET London, Savoy Place in spring 2021 and a prize fund of £350,000 will be awarded to support further research led by the recipient.
Further details of the IET and A F Harvey Engineering Research Prize can be found here: www.theiet.org/harvey
Chris Hancock, Founder and Chief Technology Officer of Creo, commented: "I am honoured to have been put forward for the IET Harvey award and to have been shortlisted. I'm also extremely excited about the research I plan to undertake if successful, developing a very interesting method of controlling cell behaviour in a totally non-invasive manner. This technology would complement the Creo advanced energy platform and also benefit from the desire and drive to rapidly develop ideas into products that can really make a difference and help people all over the world."
Craig Gulliford, Chief Executive Officer of Creo, commented: "I would like to congratulate Chris on this prestigious nomination. This is a proud moment for Creo Medical and it is fantastic to see Chris recognised for his achievements and the research and development he has conducted for over 20 years. I wish him the best of luck and look forward to hearing of the result in December."
Enquires:
Creo Medical Group plc | investors.creomedical.com |
Richard Rees (CFO) | +44 (0)1291 606 005 |
|
|
Cenkos Securities plc | +44 (0)20 7397 8900 |
Stephen Keys / Cameron MacRitchie (NOMAD) |
|
Michael Johnson / Russell Kerr (Sales) |
|
|
|
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
Paul McManus / Lianne Cawthorne | Mob: +44 (0)7980 541 893 / +44 (0)7515 909 238 |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA Advanced Energy Platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, investors.creomedical.com